Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats

Nutrition and Diabetes

Volumn 1, Issue 1, 2011, Pages

  Rojas, J M ^a   Printz, R L ^a   Niswender, K D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

brain; energy homeostasis; insulin; weight gain

Indexed keywords

GLUCOSE; INSULIN DETEMIR; INSULIN GLARGINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG POTENCY; ENERGY BALANCE; FAT MASS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HOMEOSTASIS; HYPOGLYCEMIA; INSULIN TREATMENT; LIPID DIET; LOW FAT DIET; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

EID: 84884211357     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2011.6     Document Type: Article

References (52)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128: 165-175.
4. The Diabetes Control and Complications Trial Research Group. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 1711-1721.
5. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-434.
6. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146.
7. Dunn-Meynell AA, Sanders NM, Compton D, Becker TC, Eiki J, Zhang BB et al. Relationship among brain and blood glucose levels and spontaneous and glucoprivic feeding. J Neurosci 2009; 29: 7015-7022.
8. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetesFcauses, effects and coping strategies. Diabetes Obes Metab 2007; 9: 799-812.
9. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-totarget trial comparing insulin detemir with NPH insulin as addon therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
10. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes, Obesity, and Metabolism 2007; 9: 209-217.
11. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P et al. Tissue selectivity of insulin detemir action in vivo. Diabetologia 2006; 49: 1274-1282.
12. Hallschmid M, Jauch-Chara K, Korn O, Molle M, Rasch B, Born J et al. Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 2010; 59: 1101-1107.
13. Tschritter O, Hennige AM, Preissl H, Porubska K, Schafer SA, Lutzenberger Wet al. Cerebrocortical beta activity in overweight humans responds to insulin detemir. PLoS One 2007; 2: e1196.
14. Owens DR, Bolli GB. Beyond the era of NPH insulinFlong-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008; 10: 333-349.
15. Woods SC, Seeley RJ. Insulin as an adiposity signal. Int J Obes Relat Metab Disord 2001; 25 (Suppl 5): S35-S38.
16. Bagdade JD, Bierman EL, Porte Jr D. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967; 46: 1549-1557.
17. Niswender KD, Baskin DG, SchwartzMW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004; 15: 362-369.
18. Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2-40.
19. Plum L, Belgardt BF, Bruning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest 2006; 116: 1761-1766.
20. Woods SC, Lotter EC, McKay LD, Porte Jr D. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979; 282: 503-505.
21. Niswender KD, Morrison CD, Clegg DJ, Olson R, Baskin DG, Myers Jr MG et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia. Diabetes 2003; 52: 227-231.
22. Air EL, Benoit SC, Blake Smith KA, Clegg DJ, Woods SC. Acute third ventricular administration of insulin decreases food intake in two paradigms. Pharmacol Biochem Behav 2002; 72: 423-429.
23. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289: 2122-2125.
24. Masaki T, Chiba S, Noguchi H, Yasuda T, Tobe K, Suzuki R et al. Obesity in insulin receptor substrate-2-deficient mice: disrupted control of arcuate nucleus neuropeptides. Obes Res 2004; 12: 878-885.
25. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
26. Posey K, Clegg DJ, Printz RL, Byun J, Morton GJ, Vivekanandan-Giri A et al. Hypothalamic proinflammatory lipid accumulation, inflammation, and insulin resistance in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009; 296: E1003-E1012.
27. Sorensen AR, Stidsen CE, Ribel U, Nishimura E, Sturis J, Jonassen I et al. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor. Diabetes Obes Metab 2010; 12: 665-673.
28. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT,Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007; 56: 1025-1033.
29. Dryden S, Pickavance L, Henderson L, Williams G. Hyperphagia induced by hypoglycemia in rats is independent of leptin and hypothalamic neuropeptide Y (NPY). Peptides 1998; 19: 1549-1555.
30. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
31. Galassetti P, Davis SN. Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond) 2000; 99: 351-362.
32. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001; 2: 282-286.
33. O'Brien RM, Granner DK. Regulation of gene expression by insulin. Biochem J 1991; 278 (Part 3): 609-619.
34. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949.
35. Woods SC, Porte Jr D. Relationship between plasma and cerebrospinal fluid insulin levels of dogs. Am J Physiol 1977; 233: E331-E334.
36. Bernstein IL, Lotter EC, Kulkosky PJ, Porte Jr D, Woods SC. Effect of force-feeding upon basal insulin levels of rats. Proc Soc Exp Biol Med 1975; 150: 546-548.
37. Huizinga MM, Niswender KD, Gebretsadik T, Rothman RL, Shintani AK, Elasy TA. Insulin use and weight maintenance in well-controlled type 2 diabetes: a prospective cohort study. Obesity (Silver Spring) 2008; 16: 1933-1937.
38. Destefano MB, Stern JS, Castonguay TW. Effect of chronic insulin administration on food intake and body weight in rats. Physiol Behav 1991; 50: 801-806.
39. Panksepp J, Pollack A, Krost K, Meeker R, Ritter M. Feeding in response to repeated protamine zinc insulin injections. Physiol Behav 1974; 14: 487-493.
40. Woodward CJ, Emery PW. Energy balance in rats given chronic hormone treatment. 1. Effects of long-acting insulin. Br J Nutr 1989; 61: 437-444.
41. MacKay EM, Callaway JW, Barnes RH. Hyperalimentation in normal animals produced by protamine insulin. J Nutr 1940; 20: 59-66.
42. Kanarek RB, Marks-Kaufman R, Lipeles BJ. Increased carbohydrate intake as a function of insulin administration in rats. Physiol Behav 1980; 25: 779-782.
43. Larue-Achagiotis C, Goubern M, Laury MC. Concomitant food intake and adipose tissue responses under chronc insulin infusion in rats. Physiol Behav 1988; 44: 95-100.
44. Brandes JS. Insulin induced overeating in the rat. Physiol Behav 1977; 18: 1095-1102.
45. Lotter EC, Woods SC. Injections of insulin and changes of body weight. Physiol Behav 1977; 18: 293-297.
46. VanderWeele DA, Haraczkiewicz E, Van Itallie TB. Elevated insulin and satiety in obese and normal-weight rats. Appetite 1982; 3: 99-109.
47. Fritsche A, Haring H. At last, a weight neutral insulin? Int J Obes Relat Metab Disord 2004; 28 (Suppl 2): S41-S46.
48. Tibaldi J. Actions of insulin beyond glycemic control: a perspective on insulin detemir. Adv Ther 2007; 24: 868-882.
49. Banks WA, Morley JE, Lynch JL, Lynch KM, Mooradian AD. Insulin detemir is not transported across the blood-brain barrier. Peptides 2010; 31: 2284-2288.
50. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
51. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753-1760.
52. Pfutzner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C et al. The switch from sulfonylurea to preprandial short-acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2006; 8: 375-384.